<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04263415</url>
  </required_header>
  <id_info>
    <org_study_id>sema in PCOS</org_study_id>
    <nct_id>NCT04263415</nct_id>
  </id_info>
  <brief_title>The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity</brief_title>
  <official_title>The Effects of Semaglutide on Modulation of Taste Sensitivity, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Responses in Women With PCOS and Obesity: a Randomized, Single-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore the effects of GLP-1 receptor agonist (GLP-1 RA)&#xD;
      semaglutide on modulation of taste sensitivity, tongue tissue transcriptome, modulation of&#xD;
      neural response in central reward processing regions and gastric emptying rate. In addition,&#xD;
      we aim to investigate the associations between semaglutide induced modulation of taste&#xD;
      sensitivity, neural responses and gastric emptying with changes in body mass, eating-&#xD;
      behavioural pattern, food perception and food intake.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2, 2019</start_date>
  <completion_date type="Actual">May 31, 2020</completion_date>
  <primary_completion_date type="Actual">May 8, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a randomized, single-blind, placebo-controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The impact of sema on taste and tongue transcriptome</measure>
    <time_frame>Changes in taste sensations using Taste-Streeps and tongue transcriptome using RNA-seq from baseline up to the end of 12th week.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The impact of sema on gastric emptying.</measure>
    <time_frame>Change in gastric emptying from baseline up to the end of 12th week.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The impact of sema on neural response in central reward processing regions</measure>
    <time_frame>fMRI change in neural response from baseline to the end of 12th week of therapy.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>PCOS</condition>
  <condition>Semaglutide</condition>
  <condition>Taste, Altered</condition>
  <condition>Tongue Tissue Transcriptome</condition>
  <condition>Gastric Emptying</condition>
  <condition>Central Neural Response</condition>
  <arm_group>
    <arm_group_label>group P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once-weekly injection with placebo pen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once-weekly application of semaglutide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>semaglutide inrun period of 4 weeks with 0.5mg/week s.c. followed by 1mg/week sc for 12 weeks</description>
    <arm_group_label>group S</arm_group_label>
    <other_name>Ozempic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once-weekly injection with placebo pen for 16 weeks</description>
    <arm_group_label>group P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed written consent&#xD;
&#xD;
          -  Diagnosed with PCOS by Rotterdam criteria&#xD;
&#xD;
          -  BMI &gt; 30 kg/m2&#xD;
&#xD;
          -  Age 18 years-menopause&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe psychiatric disease including schizophrenia, paranoid psychosis, bipolar&#xD;
             disorder or mental retardation&#xD;
&#xD;
          -  Current history of neurological disease including traumatic brain surgery&#xD;
&#xD;
          -  Current history of diagnosis of type I or type II diabetes or plasma haemoglobin A1c&#xD;
             6.5% at inclusion&#xD;
&#xD;
          -  Impaired hepatic function (liver transaminases&gt;3 times upper normal limit)&#xD;
&#xD;
          -  Impaired renal function (estimated glomerular filtration rate (eGFR)&lt; 50 ml/min&#xD;
&#xD;
          -  Impaired pancreatic function (any history of acute or chronic pancreatitis and/or&#xD;
             amylase &gt;2 times upper limit)&#xD;
&#xD;
          -  Bleeding disorders&#xD;
&#xD;
          -  Women who are pregnant, breast feeding or have intention of becoming pregnant within&#xD;
             the next 9 months&#xD;
&#xD;
          -  Women who are planning any operation within the next 6 months&#xD;
&#xD;
          -  History of medullary thyroid carcinoma (MTC) and/or family history with MTC and/or&#xD;
             multiple endocrine neoplasia syndrome type 2&#xD;
&#xD;
          -  Cardiac problems defined as decompensated heart failure (New York Herat Association&#xD;
             functional class III or IV), unstable angina pectoris, and/or myocardial infarction&#xD;
             within the last 12 months&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure &gt; 180 mmHg, diastolic blood&#xD;
             pressure &gt; 110 mmHg&#xD;
&#xD;
          -  Receiving GLP-1 agonist within the last 12 months&#xD;
&#xD;
          -  Use of any weight-lowering pharmacotherapy within the preceding 3 months&#xD;
&#xD;
          -  Contraindication for MR scanning (magnetic implants, pacemaker, claustrophobia etc)&#xD;
&#xD;
          -  Any condition that the investigator feels would interfere with trial participation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UMC Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Andrej Janez</investigator_full_name>
    <investigator_title>Clinical professor, Head of the Department of Endocrinology, Diabetes and Metabolic Diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysgeusia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

